Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06252610 · ClinicalTrials.gov registry record
PET/MRI of Primary Sclerosing Cholangitis
A clinical trial, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- 10
- Enrollment target
NCT06252610: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT06252610 is a clinical trial that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06252610 has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- 10 participants
- Enrollment target
Study Summary
This study aims to use positron emission tomography (PET)/magnetic resonance imaging (MRI) to diagnose and quantify PSC-related biliary tract fibrosis and to improve upon the currently available non-invasive diagnostic capabilities by investigating the ability of combined PET/MRI to detect and quantify fibrosis using a novel collagen-binding radiotracer. Specifically, the investigators will be comparing \[68Ga\]CBP8- and \[18F\]-FAPI-74 PET/MRI to a liver transient elastography scan in the diagnosis of biliary tree fibrosis.
Primary Outcome
To establish the diagnostic capabilities (sensitivity, specificity, accuracy) of PET/MRI using \[68Ga\]CBP8 or \[18F\]-FAPI-74 for detection of the fibrotic component in patients with PSC.
Interventions
- DRUG Radiotracer Injection
- DIAGNOSTIC_TEST Imaging
- DRUG Contrast Media, Magnetic Resonance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-05-10 |
| Est. Completion | 2029-04-30 |
What is known before NCT06252610 opens enrollment
NCT06252610 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Radiotracer Injection is the first listed.
NCT06252610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06252610 about?
NCT06252610 is a clinical study titled "PET/MRI of Primary Sclerosing Cholangitis". This study aims to use positron emission tomography (PET)/magnetic resonance imaging (MRI) to diagnose and quantify PSC-related biliary tract fibrosis and to improve upon the currently available non-invasive diagnostic capabilities by investigating the ability of combined PET/MRI to detect and quant...
What is the current status of trial NCT06252610?
This trial is currently not yet recruiting. The enrollment target is 10 participants. The study started on 2026-05-10. Estimated completion is 2029-04-30.
What interventions are being tested in trial NCT06252610?
The interventions under investigation include: Radiotracer Injection (DRUG), Imaging (DIAGNOSTIC_TEST), Contrast Media, Magnetic Resonance (DRUG).
Who is sponsoring clinical trial NCT06252610?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI